Siegfried Holding Ltd (SFZN) - Total Assets

Latest as of June 2025: CHF1.97 Billion CHF ≈ $2.49 Billion USD

Based on the latest financial reports, Siegfried Holding Ltd (SFZN) holds total assets worth CHF1.97 Billion CHF (≈ $2.49 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Siegfried Holding Ltd - Total Assets Trend (2002–2024)

This chart illustrates how Siegfried Holding Ltd's total assets have evolved over time, based on quarterly financial data. Also see Siegfried Holding Ltd (SFZN) market capitalisation for the company's overall valuation and market capitalisation.

Siegfried Holding Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Siegfried Holding Ltd's total assets of CHF1.97 Billion consist of 48.6% current assets and 51.4% non-current assets. Review Siegfried Holding Ltd debt and liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (CHF) % of Total Assets
Cash & Equivalents CHF38.76 Million 2.0%
Accounts Receivable CHF411.39 Million 21.3%
Inventory CHF387.58 Million 20.0%
Property, Plant & Equipment CHF909.99 Million 47.1%
Intangible Assets CHF55.89 Million 2.9%
Goodwill CHF0.00 0.0%

Asset Composition Trend (2002–2024)

This chart illustrates how Siegfried Holding Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SFZN stock price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Siegfried Holding Ltd's current assets represent 48.6% of total assets in 2024, an increase from 37.5% in 2002.
  • Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 5.4% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2002.
  • Asset Diversification: The largest asset category is property, plant & equipment at 47.1% of total assets.

Siegfried Holding Ltd Competitors by Total Assets

Key competitors of Siegfried Holding Ltd based on total assets are shown below.

Company Country Total Assets
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Galderma Group N
SW:GALD
Switzerland CHF12.88 Billion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.69 Billion
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
China CN¥10.21 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.84 Billion
Ningbo Menovo Pharm Co Ltd
SHG:603538
China CN¥4.73 Billion

Siegfried Holding Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.91 2.70 3.56
Quick Ratio 1.45 1.40 1.83
Cash Ratio 0.11 0.18 0.00
Working Capital CHF618.36 Million CHF606.68 Million CHF430.71 Million

Siegfried Holding Ltd - Advanced Valuation Insights

This section examines the relationship between Siegfried Holding Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.83
Latest Market Cap to Assets Ratio 1.92
Asset Growth Rate (YoY) 3.9%
Total Assets CHF1.93 Billion
Market Capitalization $3.71 Billion USD

Valuation Analysis

Above Book Valuation: The market values Siegfried Holding Ltd's assets above their book value (1.92x), reflecting positive investor sentiment about the company's future prospects.

Positive Asset Growth: Siegfried Holding Ltd's assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Siegfried Holding Ltd (2002–2024)

The table below shows the annual total assets of Siegfried Holding Ltd from 2002 to 2024.

Year Total Assets Change
2024-12-31 CHF1.93 Billion
≈ $2.44 Billion
+3.88%
2023-12-31 CHF1.86 Billion
≈ $2.35 Billion
+3.81%
2022-12-31 CHF1.79 Billion
≈ $2.27 Billion
+7.43%
2021-12-31 CHF1.67 Billion
≈ $2.11 Billion
+34.36%
2020-12-31 CHF1.24 Billion
≈ $1.57 Billion
+6.29%
2019-12-31 CHF1.17 Billion
≈ $1.48 Billion
+5.95%
2018-12-31 CHF1.10 Billion
≈ $1.39 Billion
+3.00%
2017-12-31 CHF1.07 Billion
≈ $1.35 Billion
+4.86%
2016-12-31 CHF1.02 Billion
≈ $1.29 Billion
+1.74%
2015-12-31 CHF1.00 Billion
≈ $1.27 Billion
+59.46%
2014-12-31 CHF629.57 Million
≈ $795.95 Million
+17.07%
2013-12-31 CHF537.77 Million
≈ $679.89 Million
+12.66%
2012-12-31 CHF477.36 Million
≈ $603.51 Million
+6.55%
2011-12-31 CHF448.00 Million
≈ $566.39 Million
-3.46%
2010-12-31 CHF464.05 Million
≈ $586.69 Million
-2.73%
2009-12-31 CHF477.07 Million
≈ $603.14 Million
-10.80%
2008-12-31 CHF534.81 Million
≈ $676.14 Million
-18.81%
2007-12-31 CHF658.74 Million
≈ $832.82 Million
-4.97%
2006-12-31 CHF693.20 Million
≈ $876.39 Million
+2.31%
2005-12-31 CHF677.52 Million
≈ $856.57 Million
+15.65%
2004-12-31 CHF585.82 Million
≈ $740.64 Million
-9.16%
2003-12-31 CHF644.88 Million
≈ $815.30 Million
+9.18%
2002-12-31 CHF590.67 Million
≈ $746.77 Million
--

About Siegfried Holding Ltd

SW:SFZN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$4.05 Billion
CHF3.20 Billion CHF
Market Cap Rank
#4317 Global
#67 in Switzerland
Share Price
CHF73.15
Change (1 day)
+3.54%
52-Week Range
CHF66.90 - CHF100.00
All Time High
CHF1182.00
About

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. The company offers drug substances, including exclusive synthesis that manufactures custom APIs. It also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pa… Read more